Table 3.
Distribution of tumor characteristics, and recent mammography among current users of menopausal hormone therapy by type and duration
| Therapy | Duration | |||||
| Estrogen–progestin | Estrogen alone | P valuea | <5 years | ≥ 5 years | P valuea | |
| Total | 422 | 92 | 238 | 284 | ||
| Recent mammography | ||||||
| Yes | 301 (75) | 55 (66) | 0.11 | 171 (76) | 189 (70) | 0.13 |
| No | 102 (25) | 28 (34) | 53 (24) | 80 (30) | ||
| Tumor size | ||||||
| ≤ 10 mm | 125 (30) | 23 (25) | 61 (26) | 90 (32) | ||
| 11 to 20 mm | 186 (44) | 51 (56) | 0.19 | 101 (43) | 139 (49) | 0.010 |
| 21 to 50 mm | 102 (24) | 15 (16) | 70 (30) | 49 (17) | ||
| >50 mm | 8 (2) | 2 (2) | 5 (2) | 5 (2) | ||
| Lymph node involvement | ||||||
| 0 lymph nodes | 289 (70) | 60 (67) | 162 (69) | 191 (69) | ||
| 1 to 3 lymph nodes | 86 (21) | 24 (27) | 0.38 | 47 (20) | 65 (23) | 0.36 |
| >3 lymph nodes | 39 (9) | 6 (7) | 25 (11) | 21 (8) | ||
| Grade | ||||||
| 1 | 69 (25) | 10 (15) | 21 (13) | 57 (31) | ||
| 2 | 99 (37) | 32 (48) | 0.11 | 57 (36) | 76 (42) | <0.0001 |
| 3 | 103(38) | 24 (36) | 80 (51) | 50 (27) | ||
| Histology | ||||||
| Ductal | 272 (66) | 61 (68) | 17 (74) | 166 (60) | ||
| Lobular | 69 (17) | 10 (11) | 0.37 | 34 (15) | 46 (17) | 0.0007 |
| Other | 73 (18) | 19 (21) | 27 (12) | 66 (24) | ||
| Estrogen receptor (ER), progesterone receptor (PR) status | ||||||
| ER-PR- | 45 (15) | 9 (16) | 34 (20) | 21 (11) | ||
| ER+PR- | 35 (12) | 5 (9) | 0.93 | 25 (15) | 15 (8) | 0.0062 |
| ER-PR+ | 19 (6) | 4 (7) | 13 (8) | 10 (5) | ||
| ER+PR+ | 196 (66) | 39 (68) | 99 (58) | 140 (75) | ||
Data presented as n (%). aGlobal chi-squared P value for type and duration, respectively.